Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PTPRE | P23469 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25999362 | 0.90 | NPC1 (0.39) | NPC1RAB9AEPHX2ALOX5TNKS2 | |
| SCHEMBL2706605 | 0.89 | NPC1 (0.39) | NPC1RAB9AEPHX2ALOX5PTPRE | |
| SCHEMBL12433324 | 0.88 | NPC1 (0.38) | NPC1RAB9AEPHX2ALOX5TNKS2 | |
| SCHEMBL2704989 | 0.88 | NPC1 (0.38) | NPC1RAB9AEPHX2ALOX5TNKS2 | |
| SCHEMBL15713807 | 0.87 | NPC1 (0.36) | NPC1RAB9AEPHX2ALOX5TNKS2 | |
| SCHEMBL13732770 | 0.87 | NPC1 (0.36) | NPC1RAB9AEPHX2ALOX5TNKS2 | |
| SCHEMBL2707355 | 0.86 | NPC1 (0.38) | NPC1RAB9AEPHX2ALOX5TNKS2 | |
| SCHEMBL15690506 | 0.86 | KDM4E (0.38) | NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2704987 | 0.85 | NPC1 (0.41) | NPC1RAB9AEPHX2ALOX5 | |
| SCHEMBL2707199 | 0.84 | NPC1 (0.46) | NPC1RAB9AEPHX2ALOX5PTPRE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179225-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-06-28 | — | — | US | disclosed |
| US-20160367531-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-12-22 | — | — | US | disclosed |
| US-9458150-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150307517-A1 | ANTIMICROBIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150133465-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2015-05-14 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367531-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | NPC1 516/4885RAB9A 2057/4885EPHX2 4031/4885 |
| US-20150133465-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | NPC1 516/4885RAB9A 2057/4885EPHX2 4031/4885 |
| US-20150307517-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | NPC1 516/4885RAB9A 2057/4885EPHX2 4031/4885 |
| US-20180179225-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | NPC1 516/4885RAB9A 2057/4885EPHX2 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.